Chi-Chung Li

Title: Chi-Chung Li: Innovator in Cancer Treatment

Introduction

Chi-Chung Li is a notable inventor based in South San Francisco, CA (US). He has made significant contributions to the field of cancer treatment, particularly through his innovative work on bispecific antibodies. With a total of 5 patents, his research focuses on addressing B cell proliferative disorders.

Latest Patents

Chi-Chung Li's latest patents include groundbreaking methods for dosing treatments with anti-CD20/anti-CD3 bispecific antibodies. The first patent relates to the treatment of subjects with CD20-positive cell proliferative disorders, such as non-Hodgkin's lymphomas. This invention emphasizes the intravenous administration of an anti-CD20/anti-CD3 bispecific antibody, specifically mosunetuzumab. The second patent provides methods for dosing in the treatment of cancers, particularly B cell proliferative disorders, utilizing anti-cluster of differentiation 20 (CD20) and anti-cluster of differentiation 3 (CD3) bispecific antibodies.

Career Highlights

Chi-Chung Li is currently associated with Genentech, Inc., a leading biotechnology company known for its innovative approaches to drug development. His work at Genentech has positioned him at the forefront of cancer research, contributing to advancements in therapeutic strategies.

Collaborations

Throughout his career, Chi-Chung Li has collaborated with esteemed colleagues, including Yu-Waye Chu and Iraj Hosseini. These collaborations have fostered a dynamic research environment, enhancing the development of effective cancer treatments.

Conclusion

Chi-Chung Li's contributions to the field of cancer treatment through his patents and work at Genentech, Inc. highlight his commitment to improving patient outcomes. His innovative approaches continue to pave the way for advancements in the treatment of B cell proliferative disorders.